Details of the Drug Combination

General Information of Drug Combination (ID: DCBBS20)

Drug Combination Name
Leucovorin UFT
Indication
Disease Entry Status REF
Colorectal Cancer Phase 1 [1]
Component Drugs Leucovorin   DMUAZWG UFT   DMX3O0D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Leucovorin
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [2]
Pervasive developmental disorder 6A00-6A0Z Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Megaloblastic anemia N.A. Investigative [2]
Methotrexate toxicity N.A. Investigative [2]
Leucovorin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [4]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [5]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Indication(s) of UFT
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [3]
UFT Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
UFT Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00209742) Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
2 Leucovorin FDA Label
3 Clinical pipeline report, company report or official report of Taiho Pharmaceutical.
4 Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
5 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
6 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
7 UFT Capsules (uracil-tegafur).
8 Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas. 2006 Aug;33(2):142-7. doi: 10.1097/01.mpa.0000226882.48204.26.